Mycophenolate Mofetil for Eosinophilic Fasciitis
Elizabeth Tkachenko, Alexa B. Steuer, Kelly Lo, Avery LaChance, Joseph F. Merola, Alisa N. Femia, Ruth Ann Vleugels
Abstract
Eosinophilic fasciitis (EF) is a fibrosing disorder characterized by edema, erythema, and induration of the extremities. Eosinophilic fasciitis can cause substantial morbidity from joint contractures, and permanent fibrosis may ensue without timely treatment. 1 Corticosteroids are considered firstline therapy; however, long-term treatment with corticosteroidsparing agents is required to avoid sequelae of chronic steroid use and achieve a durable clinical response. Although methotrexate is often considered the first-line corticosteroidsparing agent for EF, there is no standardized treatment ladder. To our knowledge, 3 cases of EF have reported favorable outcomes with mycophenolate mofetil (MMF) to date. Given the paucity of data, we investigated the clinical response of EF to MMF in 3 tertiary care centers.